• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

    7.710 -0.190 (-2.41%)
    Streaming Delayed Price Updated: 12:45 PM EDT, May 5, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Sagimet Biosciences Inc. - Series A Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Provides Strategic and Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
    Phase 1 clinical trial to evaluate the pharmacokinetics (PK) of a combination of denifanstat and resmetirom expected to initiate in 2H 2025; data readout expected 1H 2026 
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.